Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVE AND METHOD: To estimate drug costs of treating visceral leishmaniasis (VL) based on data on the VL population structure from the high-burden, antimony-resistant area of Northern Bihar, India. RESULTS: Paromomycin is the cheapest option ($7450 to treat 1000 patients). Treating 1000 patients with oral miltefosine would cost $119,250 at the current private market price or $64,383-$75,129 at preferential public sector price depending on the size of the order. With AmBisome it would be $163,600 or $229,500 depending on the dose (10 or 15 mg/kg total). These costs are without considering other direct costs (daily intramuscular injections for 3 weeks for paromomycin; intravenous devices and hospitalization for AmBisome; directly observed treatment if applied for miltefosine) and indirect costs. CONCLUSION: These calculations provide useful basic information for projections.

Original publication

DOI

10.1111/j.1365-3156.2008.02195.x

Type

Journal article

Journal

Tropical medicine & international health : TM & IH

Publication Date

01/2009

Volume

14

Pages

88 - 92

Addresses

UNICEF/UNDP/WB/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland. olliarop@who.int

Keywords

Humans, Leishmaniasis, Visceral, Body Weight, Phosphorylcholine, Amphotericin B, Paromomycin, Liposomes, Antiprotozoal Agents, Anthropometry, Age Distribution, Sex Distribution, Dose-Response Relationship, Drug, Adolescent, Adult, Aged, Middle Aged, Child, Child, Preschool, Infant, Drug Costs, India, Female, Male